|
Breast
Adjuvant
NSABP B-43 - A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Beth CIRG 011 - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
ECOG 5103 - A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
CALGB 40101 - Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycls) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Noves: A 2x2 Factorial Phasse III Randomized Study
Adjuvant or Hormone
LCCC 0801 - Evaluating the Role of Genotype in Tamoxifen Therapy for Breast Cancer. Contact the Clinical Research Office at (336) 832-0821 for more information.
CTSU ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx TrialVirgo AVF 4349n - An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer. Contact the Clinical Research Office at (336) 832-0821 for more information.
Cancer Control, Non Treatment
Virgo AVF 4349n - An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer. Contact the Clinical Research Office at (336) 832-0821 for more information.
Fatigue
Neoadjuvant
NSABP B-41 - A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.
Metastatic
CALGB 40502 - A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
CALGB 40503 - Endocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Traial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab for Women with Hormone Receptor-Positive Advanced Breast Cancer
LPT111110 - A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ERBB2 Overexpressing Metastatic Breast Cancer.
Hormone
IBCSG 25-02 - Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women with Endocrine-Responsive Breast Cancer
Cancer Control
Non Treatment
CCCWFU 97106 - A Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors. Reopened for Minorities
|